Immediate Impact
51 standout
Citing Papers
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
Leveraging artificial intelligence in vaccine development: A narrative review
2024 Standout
Works of Sara J. Grethlein being referenced
A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus–associated head and neck squamous cell cancer.
2018
Response of myasthenia gravis to rituximab in a patient with non‐Hodgkin lymphoma
2004
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Sara J. Grethlein | 41 | 26 | 122 | 139 | 45 | 17 | 295 | |
| Morgan Bonds | 43 | 36 | 62 | 77 | 8 | 19 | 309 | |
| John L. Vaughn | 138 | 18 | 85 | 55 | 23 | 28 | 303 | |
| Ali Khan | 16 | 73 | 73 | 110 | 6 | 33 | 315 | |
| Winnie Magadi | 62 | 46 | 31 | 48 | 22 | 14 | 243 | |
| Mallorie B. Heneghan | 57 | 30 | 68 | 59 | 31 | 19 | 328 | |
| Kristina D. Woodhouse | 59 | 91 | 52 | 47 | 19 | 26 | 254 | |
| Suhui Li | 26 | 12 | 123 | 26 | 9 | 22 | 321 | |
| Salman Ahmed | 36 | 22 | 45 | 85 | 5 | 18 | 279 | |
| Uzor C. Ogbu | 48 | 31 | 71 | 60 | 12 | 25 | 329 | |
| Alyssa Howren | 60 | 19 | 55 | 44 | 17 | 27 | 309 |
All Works
Loading papers...